GlassScriptPhysician profile
Carrie Flowers
NPI 1790907707
$4,339.12
in general payments reported to CMS, 2019-2025
28 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $723 · 2022: $795 · 2023: $664 · 2024: $1,010 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,821.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,107.63 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Madrigal Pharmaceuticals | $569.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $531.66 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $300.55 | 2023-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $186.04 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $178.66 | 2025 | Iqirvo |
| Celgene Corporation | $169.96 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $141.04 | 2021-2024 | Dificid |
| Gilead Sciences, INC. | $137.07 | 2024 | |
| Intercept Pharmaceuticals, INC. | $128.45 | 2022-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $125.65 | 2021-2025 | Entyvio |
| Ardelyx, INC. | $118.86 | 2022-2025 | Ibsrela |
| Novo Nordisk INC | $93.68 | 2025 | Wegovy, Saxenda |
| Aimmune Therapeutics, INC. | $79.97 | 2024-2025 | Vowst, Zenpep |
| Regeneron Healthcare Solutions, INC. | $76.90 | 2022-2025 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $63.07 | 2024-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $50.94 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $47.03 | 2025 | |
| Janssen Biotech, INC. | $42.58 | 2022-2025 | Tremfya |
| Pharmacosmos Therapeutics INC. | $33.40 | 2021 | |
| Ironwood Pharmaceuticals, INC | $29.34 | 2024 | |
| Kerecis Limited | $25.20 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Pfizer INC. | $22.90 | 2021 | |
| Evoke Pharma, INC. | $20.46 | 2023 | Gimoti |
| Mayne Pharma Commercial LLC | $17.25 | 2023 | |
| Nestle Healthcare Nutrition INC. | $15.19 | 2022 | |
| Redhill Biopharma INC. | $12.85 | 2023 | |
| Ferring Pharmaceuticals INC. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Flowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.